clinical trial · NCT00097786
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Diabetes Mellitus, Type 2Valsartan 160 mg + nateglinide 60 mgValsartan 160 mg + nateglinide placeboNateglinide 60 mg + valsartan placeboValsartan placebo + nateglinide placebo
brief summary
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.
started
Jan 1, 2002
primary completion
Oct 1, 2009
completion
Oct 1, 2009
last updated
Nov 8, 2023
official title
A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol